

From: Tull, Lori
Sent: Thursday, May 12, 2016 10:19 AM
To: Wouter Van't Hof (wvanthof@clevelandcordblood.org)
Subject: Clinical Information request for Cleveland Cord Blood BLA

Hi Wouter,

Would you please respond to the following request our clinical reviewer?
As discussed in the FDA letter dated 05/28/2014, the BLA should contain a statement (see below) specifying your post-marketing surveillance plan; however, we haven't been able to

locate the information about your post-marketing surveillance plan in the BLA.

Please either

indicate where this information is located in the BLA, or submit an amendment stating that you

agree to conduct the following post-marketing surveillance if CleveCord HPC, Cord Blood is

licensed in the U.S.:

a. Implement a safety outcomes monitoring and analysis plan. This plan will include: 1)

maintenance of an observational database to include, for all HPC, Cord Blood units released, information including but not limited to, time to neutrophil recovery, graft

failure, survival, cause of death, infusion reactions, and other adverse

experiences; 2)

aggregate analyses of interval and cumulative adverse experience reports; and 3) safety

outcomes analyses of interval and cumulative data that address early mortality, graft

failure-related mortality, graft failure, time to neutrophil recovery, infusion-related

events, and other adverse experiences. Reports will include a description of the population analyzed, results of the analyses, whether outcomes indicators were triggered and, if so, what actions were implemented as a result.

b. Submit to FDA a 15-day "alert report" for each serious infusion reaction associated with

administration of HPC, Cord Blood.

Best Regards,

Lori Tull

Team Lead

Regulatory Management Staff

Office of Cellular, Tissue, and Gene Therapies

Center for Biologics Evaluation and Research

(240) 402-8361

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS

ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED,

CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not

the addressee, or a person authorized to deliver the document to the addressee, you are hereby

notified that any review, disclosure, dissemination, copying, or other action based on the content

of this communication is not authorized. If you have received this document in error, please

immediately notify the sender immediately by e-mail or phone.